Logo image
Se connecter
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Article de revue   Avec comité de lecture

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Olivier Tournilhac, Solene Lecolant, Maya Hacini, Krimo Bouabdallah, Sebastien Bailly, Kamel Laribi, Thibaut Belmondo, Marie Maerevoet, Loic Ysebaert, Stéphanie Guidez, …
Blood, Vol.140(Supplement 1), pp.2302-2305
15/11/2022

Indicateurs

1 Consultations de la notice

Détails

Logo image